ExpreS2ion announces the publication of a proof of concept in animals for a new potential breakthrough malaria vaccine
ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces the publication of a scientific article in Cellular Microbiology providing the first proof of concept in an animal model for a next generation malaria vaccine that is targeting a recently discovered molecular ’key’ that the deadly malaria parasite uses to enter human blood cells.
The publication was authored by an international team, including scientists from ExpreS2ion, led by the Walter and Eliza Hall Institute of Medical Research (“WEHI”). The proof of concept presented in the article provides documentation, which could contribute to the development of vaccines based on a patent co-owned by WEHI and ExpreS2ion.
“This is the first time this type of vaccine has been shown to work in an animal model. As such, it is an important step towards developing human vaccines that aim at eradicating malaria. It is particularly gratifying that the article has been published today on April 25, which is the WHO World Malaria Day” says ExpreS2ion’s CEO Dr. Steen Klysner.
The malaria ‘key’ was first described in a Nature article, published December 2018 from the group. It is a complex of three parasite proteins called Rh5, CyRPA and Ripr, where the three proteins work together to unlock and enter the cell. This central role in the infection of human blood cells makes the complex a new and promising target for vaccine development.
The article can be found at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/cmi.13030
Malaria facts (WHO)
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected female Anopheles mosquitoes. It is preventable and curable, but never the less there were an estimated 219 million cases of malaria in 87 countries and the estimated number of deaths caused by malaria was 435,000 in 2017. See also “The World Malaria Day”: https://www.who.int/campaigns/world-malaria-day/world-malaria-day-2019
Certified Adviser
Sedermera Fondkommission
E-post: CA@sedermera.se
Telefon: +46 40-615 14 10
For further information about ExpreS2ion Biotech Holding AB, please contact:
Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.
Tags: